Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Stanford University
Mayo Clinic
University of Washington
City of Hope Medical Center
Sun Yat-sen University
University of Kentucky
Latin American Cooperative Oncology Group
Sun Yat-sen University
Apollomics Inc.
City of Hope Medical Center
Fundación GECP
Actuate Therapeutics Inc.
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Eastern Cooperative Oncology Group
Genentech, Inc.
University of Colorado, Denver
Seoul St. Mary's Hospital
M.D. Anderson Cancer Center
Zhejiang Cancer Hospital
Soroka University Medical Center
Hebei Medical University
University of Pittsburgh
Novartis
DEKK-TEC, Inc.
Instituto Nacional de Cancerologia de Mexico
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
AIO-Studien-gGmbH
UNC Lineberger Comprehensive Cancer Center
Dana-Farber Cancer Institute
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
Hellenic Cooperative Oncology Group
GE Healthcare
Zhejiang Cancer Hospital
Pharmacyclics LLC.
National Cancer Institute (NCI)
Swiss Cancer Institute
University College, London
Clinical Research Center for Solid Tumor, Korea